Compare EGY & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EGY | CRVS |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.7M | 1.2B |
| IPO Year | 1996 | 2016 |
| Metric | EGY | CRVS |
|---|---|---|
| Price | $5.36 | $12.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.30 | ★ $30.17 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $359,272,000.00 | N/A |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $29.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.16 | $3.55 |
| 52 Week High | $6.72 | $26.95 |
| Indicator | EGY | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 34.80 | 40.84 |
| Support Level | $5.01 | $11.42 |
| Resistance Level | $5.38 | $19.21 |
| Average True Range (ATR) | 0.20 | 1.06 |
| MACD | -0.09 | -0.17 |
| Stochastic Oscillator | 5.20 | 24.03 |
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.